INTRODUCTION
============

In 2013, the Kidney Disease: Improving Global Outcomes work group recommended clinical laboratories to report estimated glomerular filtration rate (eGFR) in adults using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation \[[@sfaa039-B1]\], unless an alternative equation improves accuracy of glomerular filtration rate (GFR) estimates \[[@sfaa039-B2]\]. This recommendation has made the use of CKD-EPI common practice in many hospitals. However, there is evidence suggesting that GFR estimations based on creatinine can be improved in patients with known or suspected chronic kidney disease (CKD) \[[@sfaa039-B3]\]. Moreover, the CKD-EPI equation is not intended for the entire life span, as the present formulation of the equation severely overestimates GFR in children \[[@sfaa039-B10], [@sfaa039-B11]\]. This restricted scope of the CKD-EPI equation also most likely explains its substantial overestimation and low accuracy among young adults \[[@sfaa039-B6], [@sfaa039-B11], [@sfaa039-B12]\], and the implausible changes in eGFR when switching from the recommended creatinine-based Chronic Kidney Disease in Children equation ('Schwartz bedside\') in paediatric care to CKD-EPI in adults \[[@sfaa039-B13]\]. Thus, although GFR estimation based on creatinine has a long history \[[@sfaa039-B14]\], it seems to still be an area where improvements can be made. Guidance in future refinement of GFR equations and estimation approaches are warranted from more solid empirical evidence from external validation studies.

It is essential to distinguish between 'diagnostic correctness' and 'diagnostic predictiveness' when investigating GFR estimation accuracy \[[@sfaa039-B15]\]. Diagnostic correctness represents GFR estimation accuracy stratified by measured GFR (clearance of external tracers, mGFR) and is analogous to sensitivity and specificity of a binary test. For binary tests, there is a trade-off between sensitivity and specificity, which for GFR equations corresponds to a trade-off between accuracy of eGFR among patients with and without renal impairment \[[@sfaa039-B15], [@sfaa039-B16]\]. However, when a diagnostic test is used in clinical practice typically, the index test (eGFR) but not the reference method (mGFR) is available. Diagnostic predictiveness represents GFR estimation accuracy stratified by eGFR, analogous to presenting predictive values of a binary test for use in the clinical situation \[[@sfaa039-B15]\]. Diagnostic predictiveness is dependent not only on sensitivity (accuracy at low mGFR) and specificity (accuracy at normal mGFR), but also on the clinical setting, e.g. primary versus specialized healthcare and the resulting distribution of patient characteristics, symptomatology and severity of renal disease \[[@sfaa039-B15], [@sfaa039-B17]\]. Most validation studies of GFR equations have focused on diagnostic correctness \[[@sfaa039-B15], [@sfaa039-B18]\] and have often pooled data from different populations. However, overall validation in pooled data adds little insight into diagnostic predictiveness, as the pooling makes the study population and underlying clinical setting poorly defined \[[@sfaa039-B19]\]. Additionally, few studies have studied diagnostic accuracy at two or more dimensions simultaneously, e.g. mGFR and age \[[@sfaa039-B9], [@sfaa039-B13], [@sfaa039-B20]\].

The overall aim of the present cross-sectional multicentre study was to assess if and to what extent diagnostic predictiveness of GFR estimation based on creatinine can be improved in two distinct clinical settings: (i) patients with high prior likelihood of CKD and (ii) patients with low prior likelihood of CKD. We compared CKD-EPI with one GFR equation developed specifically for use in patients with suspected or confirmed CKD \[the Lund--Malmö revised equation (LMR)\] \[[@sfaa039-B21]\] and one primarily intended for use in patients with no prior suspicion of CKD \[the Full Age Spectrum (FAS) equation\] \[[@sfaa039-B7], [@sfaa039-B22]\].

MATERIALS AND METHODS
=====================

Patient data
------------

The European Kidney Function Consortium (EKFC), a new working group under the umbrella of the ERA-EDTA, has taken the initiative to pool and structure data on mGFR, plasma/serum creatinine, age, sex, height and weight of Europeans and non-black North Americans aged ≥18 years. Data were obtained from 11 cohorts ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S1](#sup1){ref-type="supplementary-material"}) used in ongoing or published cross-sectional and longitudinal studies in France \[[@sfaa039-B7], [@sfaa039-B8], [@sfaa039-B23], [@sfaa039-B24]\], the UK \[[@sfaa039-B7], [@sfaa039-B25]\], Germany \[[@sfaa039-B7], [@sfaa039-B26]\], Norway \[[@sfaa039-B7], [@sfaa039-B8], [@sfaa039-B27]\], Sweden \[[@sfaa039-B4], [@sfaa039-B6], [@sfaa039-B9], [@sfaa039-B28], [@sfaa039-B29]\] and the USA \[[@sfaa039-B7], [@sfaa039-B8], [@sfaa039-B30], [@sfaa039-B31]\]. We classified the individual cohorts according to the clinical setting: (i) patients with high prior likelihood of CKD (labelled 'CKD cohorts'; *n* = 5) and (ii) patients with low prior likelihood of CKD (labelled 'community cohorts'; *n* = 6). Common causes for referral in the CKD cohorts were manifest or suspected diabetic nephropathy, interstitial nephritis, glomerulonephritis, nephrotic syndrome, haematuria, proteinuria, reflux nephropathy, myeloma, vasculitis, consideration of initiation of haemodialysis, control after organ transplantation and to dose drugs cleared by the kidneys. The community cohorts included studies of general populations, healthy older people and potential kidney donors.

Patient data were pooled in an anonymous database for the present study at Lund University, Sweden. All procedures involving subjects and data followed the ethical principles for medical research involving human subjects established in the World Medical Association Declaration of Helsinki. For this type of retrospective study, all extracted data were fully anonymous without any personal information, therefore informed consent was not required according to the Regional Ethical Board approval in Lund, Sweden, which approved the study (Dnr 2018/220). The present study was limited to the first measurement of GFR in each patient, resulting in 8365 patients in the CKD cohorts (median age 60 years, 45% females, median mGFR 58 mL/min/1.73 m^2^) and 6759 patients in the community cohorts (median age 59 years, 55% females, median mGFR 88 mL/min/1.73 m^2^; [Table 1](#sfaa039-T1){ref-type="table"}).

###### 

Patient characteristics in the CKD and community cohorts

  Variables                              CKD cohorts (*n* = 8365)   Community cohorts (*n* = 6759)
  ------------------------------------- -------------------------- --------------------------------
  Age, years                                   60 (18--84)                   59 (30--84)
  Females, *n* (%)                              3758 (45)                     3722 (55)
  Weight, kg                                   75 (45--118)                  75 (50--112)
  Height, cm                                  170 (151--188)                168 (152--186)
  Body surface area, m^2^                   1.86 (1.42--2.34)             1.85 (1.49--2.30)
  BMI, kg/m^2^                                 25 (17--40)                   26 (19--38)
  Plasma/serum creatinine, μmol/L             102 (46--377)                  70 (47--122)
  mGFR, mL/min/1.73** **m^2^                   58 (12--123)                  88 (41--128)
  mGFR, *n* (%), mL/min/1.73** **m^2^                              
   \<30                                         1752 (21)                      30 (0.4)
   30--44                                       1310 (16)                     206 (3.0)
   45--59                                       1279 (15)                     452 (6.7)
   60--89                                       2306 (28)                     2891 (43)
   90--119                                      1426 (17)                     2824 (42)
   ≥120                                         292 (3.5)                     356 (5.3)

Descriptive measures given as median values (2.5 and 97.5 percentiles) if not stated otherwise

Laboratory methods
------------------

Details of laboratory methods used are summarized in [Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S2](#sup1){ref-type="supplementary-material"}. Clearance methods for determination of GFR (mGFR) included renal clearance of inulin, chromium-51 labelled ethylene-diamine-tetra-acetic-acid (^51^Cr-EDTA) and iothalamate, and plasma clearance of iohexol, all considered acceptable as reference tests \[[@sfaa039-B32]\]. Samples of creatinine were obtained on the day of GFR measurement in all cohorts but Stockholm, where samples within 48 h of mGFR were accepted. All centres used creatinine assays traceable to isotope dilution mass spectrometry (IDMS) and standardized against primary reference material (National Institute of Standards and Technology Standard Reference Material 967), except for Kent, where it was measured directly with IDMS \[[@sfaa039-B25]\].

GFR equations
-------------

The CKD-EPI, FAS and LMR creatinine equations are presented in the [Supplementary material](#sup1){ref-type="supplementary-material"}. None of the included cohorts has been used for the development of any of the equations.

Statistical evaluation
----------------------

Statistical evaluations were conducted using SPSS Statistics (version 25; IBM Corp.), STATA (version 14; StataCorp) and R (version 3.5.2), focussing on bias, precision and accuracy \[[@sfaa039-B33]\]. 'Bias' was defined as the median of the individual differences between eGFR and mGFR in mL/min/1.73 m^2^. 'Precision' was assessed as the interquartile range (IQR) of the differences eGFR -- mGFR. 'Accuracy' was assessed from the absolute error \|eGFR -- mGFR\|/mGFR and summarized as the median absolute percentage difference (absolute accuracy) and as the percentage of estimates within ±10% and ±30% of mGFR (P~10~ and P~30~). The complementary value 1 -- P~30~ reflects the proportion of 'large' estimation errors \[[@sfaa039-B34]\]. The Kidney Disease Outcome Quality Initiative (K/DOQI) 2002 benchmark is to reach P~30~ accuracy of ≥90% \[[@sfaa039-B35], [@sfaa039-B36]\]. Equation performance was evaluated against this benchmark. We also assessed equation performance using pairwise comparisons with CKD-EPI equation as benchmark.

Non-parametric and asymptotic 95% confidence intervals (CIs) were calculated as measures of the statistical uncertainty in medians and proportions (P~10~/P~30~) of the overall results, respectively. CIs for IQR were estimated from the 2.5 to 97.5 percentiles of a simulated distribution obtained using a bootstrap method with 10 000 replications \[[@sfaa039-B37]\].

### Diagnostic correctness---stratification by mGFR

Evaluation of diagnostic correctness implies analysis of equation performance (bias, precision and accuracy) stratified by mGFR, analogous to reporting sensitivity and specificity of a binary test \[[@sfaa039-B15]\]. We collapsed the two cohort types to improve statistical precision and presented diagnostic correctness in a simultaneous stratification by mGFR (\<30, 30--59, 60--89, 90--119 and ≥120 mL/min/1.73 m^2^) and age (18--39, 40--59, 60--69 and ≥70 years). We also added sex (female and male) as a third dimension to this stratification.

### Diagnostic predictiveness---stratification by estimated GFR

Evaluation of diagnostic predictiveness implies analysis of equation performance (bias, precision and accuracy) stratified by estimated GFR, analogous to presenting predictive values of a binary test for use in the clinical situation \[[@sfaa039-B15]\]. 'Accuracy diagrams' were constructed using quantile regression with fractional polynomials (linear, logarithm and square) as input to illustrate how the estimation errors varied across eGFR for each equation in the two population types \[[@sfaa039-B15], [@sfaa039-B16]\]. In the diagrams, we expressed estimation errors in mL/min/1.73 m^2^ using the quantiles (percentiles) Q~10~, Q~50~ (median bias) and Q~90~, where the accuracy interval (AI, Q~10~--Q~90~), reflects the largest estimation error with 80% certainty. The presentation was limited to the range between 1% and 99% percentile of the estimated GFR values for each equation to limit the statistical uncertainty in the tails of the quantile curves. The constancy of bias stratified by eGFR in the accuracy diagrams is an indicator of how similarly an equation behaves in the validation compared with the original development cohort \[[@sfaa039-B16], [@sfaa039-B18]\].

Performance in a given eGFR range of each equation cannot be directly compared because it is unlikely that all evaluated equations produce GFR estimates within that range for the same set of patients \[[@sfaa039-B15]\]. Results in tables were therefore stratified by eGFR values calculated from the CKD-EPI equation (eGFR~CKD-EPI~: \<30, 30--59, 60--89, 90--119 and ≥120 mL/min/1.73 m^2^) to permit direct comparison of diagnostic predictiveness between the equations in the same patients. Since diagnostic predictiveness is dependent on pretest likelihood of disease \[[@sfaa039-B17]\], performance was evaluated for each population type (CKD and community) separately. Quantile regression was used in multivariable models to investigate how the median bias was dependent not only on eGFR~CKD-EPI~ in the intervals defined above, but also on age, sex and body mass index (BMI; \<18.5, 18.5--24.9, 25.0--29.9 and ≥30.0 kg/m^2^).

RESULTS
=======

Overall results by cohort type
------------------------------

All three equations showed no major bias overall but substantial imprecision in both the CKD and community cohorts. In the CKD cohorts, none of them reached the K/DOQI 2002 benchmark of a P~30~ accuracy ≥90%, while they all reached this benchmark in the community cohorts ([Table 2](#sfaa039-T2){ref-type="table"}). LMR had better bias, higher precision and greater accuracy than both CKD-EPI and FAS in the CKD cohorts. The P~30~ difference was seven percentage points (P~30~ = 83.5% for LMR versus 76.6% for CKD-EPI and 76.5% for FAS), which corresponds to seven fewer estimation errors exceeding 30% per 100 tested CKD patients if LMR is used. Differences between the equations in the P~10~--P~50~ accuracy range were larger in the CKD than in the community cohorts ([Figure 1](#sfaa039-F1){ref-type="fig"}). CKD-EPI was generally the most accurate equation in the community cohorts, as reflected by lower absolute percentage error and higher P~10~ than the two other equations, but the difference versus FAS was smaller than versus LMR ([Table 2](#sfaa039-T2){ref-type="table"}). Statistical evaluations of the pairwise comparisons in performance with CKD-EPI as benchmark are presented stratified by cohort type in [Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S3](#sup1){ref-type="supplementary-material"}. All comparisons had narrow CIs as a result of the large cohort sizes. Results for the 11 individual cohorts are presented in [Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S4](#sup1){ref-type="supplementary-material"}.

![The proportion of patients with sufficiently accurate estimated GFR (*y*-axis) at different requirements on highest percentage absolute error (*x*-axis), that is, from 10% to 50% (P~10~--P~50~) in relation to mGFR. (A) CKD cohorts and (B) community-based cohorts. In the example indicated by the arrows, P~20~ ranged between about 60% (CKD-EPI and FAS) and 66% (LMR) in (**A**) and was about 78% for all three equations in (B).](sfaa039f1){#sfaa039-F1}

###### 

Bias, precision, accuracy (95% CIs) of CKD-EPI, FAS and LMR in the CKD and community cohorts

  Equations                                       Bias              Precision       Absolute error (%)       P~10~ (%)           P~30~ (%)
  ---------------------------------------- ------------------- ------------------- -------------------- ------------------- -------------------
  CKD cohorts (*n*** **=** **8365)                                                                                          
   CKD-EPI                                   3.8 (3.5--4.1)     16.6 (16.1--17.0)   16.0 (15.6--16.4)    33.4 (32.3--34.4)   76.6 (75.7--77.5)
   FAS                                       3.3 (3.0--3.6)     15.5 (15.0--16.0)   15.3 (14.9--15.7)    34.3 (33.3--35.3)   76.5 (75.6--77.4)
   LMR                                      −1.4 (−1.7, −1.1)   14.4 (14.0--14.8)   14.1 (13.8--14.5)    35.9 (34.9--37.0)   83.5 (82.7--84.3)
  Community cohorts (*n*** **=** **6759)                                                                                    
   CKD-EPI                                   2.1 (1.8--2.6)     17.2 (16.7--17.7)   10.4 (10.1--10.7)    48.6 (47.4--49.8)   91.0 (90.4--91.7)
   FAS                                      −1.4 (−1.8, −1.0)   17.8 (17.3--18.3)   10.8 (10.5--11.0)    46.9 (45.7--48.0)   91.9 (91.3--92.6)
   LMR                                      −6.7 (−7.0, −6.4)   16.7 (16.2--17.1)   11.5 (11.2--11.8)    43.7 (42.5--44.9)   92.8 (92.1--93.4)

Median bias (eGFR − mGFR) and precision (IQR) expressed in mL/min/1.73** **m^2^, absolute error expressed as median absolute percentage error \|eGFR** **−** **mGFR\|/mGFR and P~10~ and P~30~ accuracy (percentage of GFR estimates within 10% and 30% of mGFR).

Diagnostic correctness---results stratified by mGFR, age and sex
----------------------------------------------------------------

LMR was generally the least biased equation at all ages in patients with known GFR (mGFR) \<90 mL/min/1.73 m^2^ ([Table 3](#sfaa039-T3){ref-type="table"}). It was generally also more precise than CKD-EPI and generally more accurate than both CKD-EPI and FAS at all mGFR levels \<90 mL/min/1.73 m^2^ ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S5A--C](#sup1){ref-type="supplementary-material"}). CKD-EPI and FAS showed marked overestimations at younger ages at all mGFR levels \<90 or 120 mL/min/1.73 m^2^, respectively ([Table 3](#sfaa039-T3){ref-type="table"}). As an example, CKD-EPI overestimated GFR by 13 mL/min/1.73 m^2^ (95% CI 11.5--15.5 mL/min/1.73 m^2^) on average in individuals \<40 years of age with mGFR 30--59 mL/min/1.73 m^2^.

###### 

**Diagnostic correctness (bias stratified by mGFR) in the two cohort types combined (CKD and community; *n* = 15** **124)**

                      Age intervals (years)                                                                                
  ----------------- -------------------------- ---------------------------------- ---------------------------------------- ----------------------------------------
  \<30, number                 101                            270                                   338                                      1073
   CKD-EPI                5.0 (3.6--7.0)                 1.4 (0.7--2.8)                        2.9 (2.1--3.9)                           2.0 (1.5--2.5)
   FAS                   9.7 (7.8--12.7)                 6.6 (5.5--7.6)                        5.6 (4.8--6.4)                           2.9 (2.5--3.3)
   LMR               ***2.8 (1.6**--**3.8)***       ***1.2 (0.4**--**1.9)***              ***1.8 (1.1**--**2.5)***                  ***0.2 (−0.2, 0.7)***
  30--59, number               381                            656                                   767                                      1443
   CKD-EPI              13.4 (11.5--15.5)                3.7 (2.6--5.0)                        3.4 (2.0--4.4)                           4.0 (3.4--4.6)
   FAS                  14.5 (13.0--16.4)                7.1 (6.0--8.3)                        2.7 (1.8--3.8)                       ***−0.2 (−0.8, 0.2)***
   LMR               ***6.3 (4.1**--**8.6)***       ***1.3 (0.3**--**2.6)***               ***0.6 (−0.9, 1.9)***                       −0.3 (−0.8, 0.5)
  60--89, number               736                            1772                                  1556                                     1133
   CKD-EPI              15.6 (13.6--17.3)                8.0 (7.3--8.9)                        7.0 (6.2--7.6)                           5.9 (5.1--5.6)
   FAS                   10.9 (9.5--12.2)                4.4 (3.8--5.1)                    ***−0.4 (−1.0, 0.3)***               **−**4.5 (**−**5.5, **−**3.8)
   LMR               ***2.6 (1.4**--**3.8)***        ***−0.1 (−0.7, 0.5)***            **−**2.2 (**−**2.7, **−**1.6)               ***−4.4 (−5.2, −3.9)***
  90--119, number              1278                           2088                 798[^a^](#tblfn4){ref-type="table-fn"}   147[^a^](#tblfn4){ref-type="table-fn"}
   CKD-EPI               10.4 (9.2--11.5)           ***−1.9 (−2.5, −1.4)***               ***−5.3 (−6.1, −4.5)***                  ***−9.5 (−12.2, −7.0)***
   FAS               ***4.4 (3.4**--**6.0)***          −2.8 (−3.4, −2.2)                     −9.5 (−10.8, −8.5)                      −14.2 (−16.8, −12.7)
   LMR                  −9.0 (−9.8, −8.3)             −12.0 (−12.5, −11.5)                  −15.1 (−16.0, −14.1)                     −20.0 (−22.3, −18.1)
  ≥120, number                 338                            249                  --[^a^](#tblfn4){ref-type="table-fn"}    --[^a^](#tblfn4){ref-type="table-fn"}
   CKD-EPI           ***−5.2 (−7.3, −2.8)***          −23.9 (−26.4, −21.2)                                                 
   FAS                  −5.8 (−9.3, −3.3)          ***−17.9 (−21.4, −15.1)***                                              
   LMR                 −25.7 (−27.0, −24.2)     **−**32.4 (**−**35.7, **−**31.0)                                           

Median bias (eGFR -- mGFR in mL/min/1.73 m^2^; 95% CIs) of CKD-EPI, FAS and LMR stratified by mGFR and age (years). The lowest bias is marked with bold and italic in each stratum.

mGFR intervals ≥120 were collapsed with 90--119 due to small numbers (*n* \< 100).

LMR exhibited noticeable underestimation in patients with mGFR \>90 mL/min/1.73 m^2^ ([Table 3](#sfaa039-T3){ref-type="table"}). CKD-EPI and FAS also yielded underestimations in patients with high mGFR but mostly to a lesser degree than LMR. LMR and CKD-EPI were both more precise than FAS at mGFR \>90 mL/min/1.73 m^2^ ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S5A](#sup1){ref-type="supplementary-material"}), but CKD-EPI was more accurate due to its lower bias ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Tables S5B and S5C](#sup1){ref-type="supplementary-material"}). None of the three equations showed any consistent differences in bias among females and males ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S6](#sup1){ref-type="supplementary-material"}).

Diagnostic predictiveness---results stratified by estimated GFR and cohort type
-------------------------------------------------------------------------------

The accuracy diagrams further illustrate the substantial imprecision across eGFR for all three equations and in both two population types ([Figure 2](#sfaa039-F2){ref-type="fig"}). Low and constant bias were seen both for LMR in the CKD cohorts and for CKD-EPI in the community cohorts at eGFR \<120 mL/min/1.73 m^2^.

![Estimation errors (eGFR -- mGFR in mL/min/1.73 m^2^ on the *Y*-axis) at different levels of eGFR on the *X*-axis (diagnostic predictiveness) in the CKD cohorts for (**A**) CKD-EPI, (**B**) FAS and (**C**) LMR and in the community cohorts for (**D**) CKD-EPI, (**E**) FAS and (**F**) LMR. The quantile regression curves for the estimation errors reflect bias (Q~50~; solid line) and estimation error with 80% certainty (accuracy interval Q~10~--Q~90~; dashed lines). Note that the curves are of different length as they are truncated at the 1 and 99% percentile of the estimated GFR values for each equation.](sfaa039f2){#sfaa039-F2}

In the CKD cohorts, LMR had lower bias and higher accuracy than CKD-EPI in patients with eGFR \>60 mL/min/1.73 m^2^ according to the CKD-EPI equation (eGFR~CKD-EPI~; [Table 4](#sfaa039-T4){ref-type="table"}). Estimates of the CKD-EPI equation \>120 mL/min/1.73 m^2^ occurred among 9% of all patients in the CKD cohorts, most of them young (median age 21 years). The overestimation exceeded 20 mL/min/1.73 m^2^ on average for these patients when CKD-EPI or FAS was used, whereas the estimates from LMR were virtually unbiased for the same patients. In particular, FAS exhibited imprecision at eGFR~CKD-EPI~ \>120 mL/min/1.73 m^2^ ([Table 4](#sfaa039-T4){ref-type="table"}).

###### 

Diagnostic predictiveness (bias, precision and accuracy stratified by eGFR) in CKD cohorts

  eGFR~CKD-EPI~              Number                      Age (years)                  BMI (kg/m^2^)                   Equation             Bias (mL/min/1.73 m^2^)    Precision (mL/min/1.73 m^2^)       Absolute error (%)            P~30~ (%)
  --------------- ----------------------------- ----------------------------- ----------------------------- ----------------------------- -------------------------- ------------------------------ ----------------------------- -------------------
  \<30                        1504                           72                            27                          CKD-EPI              ***−0.3 (−0.7, 0.0)***           6.8 (6.4--7.2)               18.1 (16.8--18.9)        74.5 (72.3--76.7)
  FAS                    2.0 (1.6--2.2)                7.0 (6.7--7.4)               19.6 (18.2--20.8)             68.4 (66.1--70.8)                                                                                               
  LMR                   −1.1 (−1.4, −0.8)           ***6.7 (6.4, 7.2)***       ***17.8 (17.0**--**18.6)***   ***77.1 (75.0**--**79.3)***                                                                                          
  30--59                      2419                           65                            27                          CKD-EPI             ***1.6 (1.2**--**2.1)***   ***12.5 (11.9**--**13.3)***    ***15.3 (14.7**--**16.0)***   78.6 (77.0--80.3)
  FAS                    1.9 (1.5--2.4)               13.5 (13.0--14.2)             15.8 (15.2--16.6)             76.6 (74.9--78.3)                                                                                               
  LMR                   −1.8 (−2.4, −1.4)             12.6 (11.9--13.1)             15.7 (14.9--16.4)        ***81.1 (79.5**--**82.7)***                                                                                          
  60--89                      2130                           58                            25                          CKD-EPI                  6.5 (5.6--7.2)             19.7 (18.9--20.8)              15.8 (14.8--16.6)        76.3 (74.5--78.1)
  FAS                    1.8 (1.0--2.7)               19.7 (18.7--20.7)             14.0 (13.3--14.5)             82.1 (80.5--83.7)                                                                                               
  LMR              ***−0.7 (−1.4**, **0.0)***    ***18.8 (18.0**--**19.9)***   ***13.8 (13.2**--**14.3)***   ***84.0 (82.4**--**85.5)***                                                                                          
  90--119                     1578                           46                            24                          CKD-EPI                 10.1 (9.2--11.2)            21.2 (20.2--22.4)              13.6 (12.7--14.6)        80.4 (78.5--82.4)
  FAS                    7.3 (6.4--8.0)               21.8 (20.5--23.2)             12.6 (12.1--13.4)             81.6 (79.6--83.5)                                                                                               
  LMR              ***−2.8 (−3.7**, **−1.8)***   ***20.8 (19.7**--**22.0)***   ***11.7 (11.1**--**12.3)***   ***90.1 (88.6**--**91.6)***                                                                                          
  ≥120                         734                           21                            21                          CKD-EPI                22.5 (20.6--23.8)       ***24.3 (22.3**--**25.8)***         21.1 (19.2--22.5)        67.0 (63.6--70.4)
  FAS                   20.4 (17.9--22.3)             33.7 (30.7--37.1)             19.6 (17.7--21.9)             65.8 (62.4--69.2)                                                                                               
  LMR              ***−0.6 (−2.9**, **1.1)***         25.2 (22.9--27.4)        ***11.2 (10.6**--**12.4)***   ***88.7 (86.4**--**91.0)***                                                                                          

Estimation results for CKD-EPI, FAS and LMR (95% CI) stratified by eGFR (mL/min/1.73 m^2^) based on the CKD-EPI equation (eGFR~CKD-EPI~). The best result for each performance marker is marked with bold and italic in each stratum. Number of patients, median age (years) and BMI (kg/m^2^) are given in each stratum Median bias (eGFR − mGFR) and precision (IQR) expressed in mL/min/1.73** **m^2^. Absolute error expressed as median absolute percentage error \|eGFR − mGFR\|/mGFR, and P~10~ and P~30~ accuracy (percentage of GFR estimates within 10% and 30% of mGFR).

In the community cohorts, changing equation from CKD-EPI to either FAS or LMR would not consistently improve accuracy in patients with eGFR~CKD-EPI~ \<120 mL/min/1.73 m^2^ (98% of all patients; [Table 5](#sfaa039-T5){ref-type="table"}). FAS exhibited increasing overestimations at high eGFR~CKD-EPI~ in the community cohorts. The underestimation of LMR varied between 4 and 7 mL/min/1.73 m^2^ across all levels of eGFR~CKD-EPI~. None of the three equations was consistently more precise than the others across all levels of eGFR~CKD-EPI~.

###### 

Diagnostic predictiveness (bias, precision and accuracy stratified by eGFR) in community cohorts

  eGFR~CKD-EPI~              Number                      Age (years)                 BMI (kg/m^2^)                  Equations            Bias (mL/min/1.73** **m^2^)   Precision (mL/min/1.73** **m^2^)       Absolute error (%)            P~30~ (%)
  --------------- ----------------------------- ----------------------------- --------------------------- ----------------------------- ----------------------------- ---------------------------------- ----------------------------- -------------------
  \<60^a^                      473                           78                           27                         CKD-EPI               ***−0.2 (−1.2, 0.6)***             12.8 (12.2--14.5)           ***13.7 (12.2**--**15.5)***   83.7 (80.4--87.1)
  FAS                   −4.3 (−5.0, −3.4)             12.2 (10.7--13.9)            13.9 (12.8--15.5)       ***85.4 (82.2**--**88.6)***                                                                                                 
  LMR                   −4.5 (−5.2, −3.3)        ***11.9 (10.9**--**13.8)***       15.1 (13.8--16.1)            82.5 (79.0--85.9)                                                                                                      
  60--89                      2479                           63                           27                         CKD-EPI              ***1.0 (0.4**--**1.7)***            18.2 (17.3--19.0)           ***11.6 (11.1**--**12.2)***   85.7 (82.4--89.0)
  FAS                   −5.8 (−6.2, −5.2)        ***15.5 (14.8**--**16.3)***       11.7 (11.2--12.2)       ***92.7 (91.6**--**93.7)***                                                                                                 
  LMR                   −7.1 (−7.6, −6.5)             16.3 (15.5--17.1)            12.4 (12.0--12.9)            91.4 (90.3--92.5)                                                                                                      
  90--119                     3687                           55                           26                         CKD-EPI                   3.0 (2.6--3.6)            ***17.0 (16.4**--**17.7)***       ***9.2 (8.9**--**9.7)***     88.9 (87.6--90.1)
  FAS               ***2.2 (1.7**--**2.7)***          18.4 (17.7--19.2)             9.6 (9.2--10.0)             92.9 (92.1--93.7)                                                                                                      
  LMR                   −7.0 (−7.6, −6.5)             17.2 (16.6--17.8)            10.7 (10.3--11.0)       ***94.8 (94.0**--**95.5)***                                                                                                 
  ≥120                         120                           29                           23                         CKD-EPI                  12.9 (6.9--15.6)           ***18.7 (15.4**--**22.5)***           12.8 (10.7--15.6)        92.5 (87.7--97.3)
  FAS                   19.3 (15.5--23.2)             26.8 (20.5--29.7)            16.3 (14.0--21.9)            73.3 (65.3--81.4)                                                                                                      
  LMR              ***−4.5 (−7.9**, **−1.8)***        19.1 (16.0--23.9)        ***9.6 (8.6**--**10.6)***   ***98.3 (94.1**--**99.8)***                                                                                                 

Estimation results for CKD-EPI, FAS and LMR (95% CI) stratified by eGFR (mL/min/1.73 m^2^) based on the CKD-EPI equation (eGFR~CKD-EPI~). The best result for each performance marker is marked with bold and italic in each stratum. Number of patients, median age (years) and BMI (kg/m^2^) are given in each stratum Median bias (eGFR − mGFR) and precision (IQR) expressed in mL/min/1.73** **m^2^. Absolute error expressed as median absolute percentage error \|eGFR − mGFR\|/mGFR, and P~10~ and P~30~ accuracy (percentage of GFR estimates within 10% and 30% of mGFR). ^a^mGFR intervals \<44 were collapsed with 45--59 due to small numbers (\<100).

Multivariable quantile regression based on eGFR~CKD-EPI~, age, sex and BMI confirmed the substantial overestimations for CKD-EPI and FAS at high levels of eGFR~CKD-EPI~ in the CKD cohorts ([Table 6](#sfaa039-T6){ref-type="table"}). Additionally, overestimation due to underweight was noted for all three equations and with similar magnitude. Age and sex did not have strong independent effects on bias for any of the three equations in the CKD cohorts. Bias varied more noticeably with eGFR~CKD-EPI~ for CKD-EPI and FAS than for LMR also in the multivariable quantile regression models for the community cohorts ([Table 6](#sfaa039-T6){ref-type="table"}). In addition, bias varied according to age for CKD-EPI and LMR. Being male increased the underestimation of the LMR equation. BMI at any level was not related to bias for any of the three equations in the community cohorts.

###### 

Diagnostic predictiveness (bias stratified for eGFR) in CKD and community cohorts

                                                     CKD cohorts        Community cohorts                                                                                                     
  --------------------------------------------- --------------------- --------------------- ------------------- -------------------------------------- -------------------------------------- --------------------------------------
  Constant[^a^](#tblfn8){ref-type="table-fn"}     1.9 (0.6 -- 3.2)      5.8 (4.6 -- 7.1)     −2.3 (−3.5, −1.1)           −10.4 (−12.5, −8.3)                     −7.7 (−9.9, −5.4)                     −16.7 (−18.8, −14.7)
  eGFR~CKD-EPI~                                                                                                                                                                               
  \<30                                                Reference             Reference            Reference       −[^b^](#tblfn9){ref-type="table-fn"}   −[^b^](#tblfn9){ref-type="table-fn"}   −[^b^](#tblfn9){ref-type="table-fn"}
  30 -- 59                                        2.0 (1.0 -- 3.0)      −0.8 (−1.8, 0.2)     −0.8 (−1.7, 0.2)              Reference (\<60)                       Reference (\<60)                       Reference (\<60)
  60 -- 89                                        6.7 (5.6 -- 7.7)      −1.3 (−2.4, −0.3)     0.2 (−0.8, 1.3)              6.1 (4.6 -- 7.7)                       0.7 (−0.9, 2.4)                        0.7 (−0.8, 2.2)
  90 -- 119                                      10.1 (8.9 -- 11.3)     3.2 (2.0 -- 4.4)     −1.4 (−2.6, −0.3)           11.8 (10.1 -- 13.4)                     9.9 (8.1 -- 11.7)                       3.6 (2.0 -- 5.2)
  ≥120                                           19.5 (17.9 -- 21.1)   14.4 (12.8 -- 16.0)    0.2 (−1.3, 1.8)            22.4 (19.2 -- 25.7)                    26.3 (22.8 -- 29.8)                     10.1 (6.9 -- 13.3)
  Age                                                                                                                                                                                         
  \<40                                                Reference             Reference            Reference                    Reference                              Reference                              Reference
  40 -- 59                                        −2.8 (−3.8, −1.7)      0.2 (−0.9, 1.2)     1.9 (0.9 -- 2.9)              −0.7 (−2.0, 0.7)                       −0.4 (−1.8, 1.0)                       3.4 (2.1 -- 4.7)
  60 -- 69                                        −1.1 (−2.2, 0.1)      −1.9 (−3.1, −0.8)    2.6 (1.6 -- 3.7)              2.5 (1.0 -- 3.9)                       −1.1 (−2.7, 0.4)                       5.7 (4.3 -- 7.2)
  ≥70                                              0.1 (−1.0, 1.2)      −3.0 (−4.0, −1.9)    2.6 (1.5 -- 3.6)             10.0 (8.3 -- 11.7)                      3.3 (1.5 -- 5.1)                      11.0 (9.4 -- 12.7)
  Female                                          −0.3 (−1.0, 0.3)      −1.3 (−1.9, −0.6)     0.2 (−0.4, 0.8)              2.6 (1.9 -- 3.3)                       1.0 (0.3 -- 1.8)                       4.2 (3.5 -- 4.8)
  BMI                                                                                                                                                                                         
  \<18.5                                          6.9 (5.4 -- 8.4)      6.8 (5.3 -- 8.3)     6.8 (5.4 -- 8.2)              −1.6 (−3.6, 0.3)                       −0.9 (−3.0, 1.2)                       −1.5 (−3.4, 0.4)
  18.5 -- 24.9                                        Reference             Reference            Reference                    Reference                              Reference                              Reference
  25.0 -- 29.9                                    −2.2 (−3.0, −1.4)     −1.9 (−2.7, −1.1)    −1.9 (−2.7, −1.2)             0.0 (−0.9, 0.8)                        −0.2 (−1.1, 0.7)                       −0.0 (−0.8, 0.8)
  ≥30.0                                           −2.5 (−3.4, −1.6)     −2.0 (−2.9, −1.1)    −2.1 (−2.9, −1.2)             −0.1 (−1.0, 0.9)                       −0.1 (−1.1, 0.9)                       0.2 (−0.8, 1.1)

Multivariable quantile regression estimates of median bias (mL/min/1.73 m^2^; 95% CI) by cohort type and subgroups of eGFR (mL/min/1.73 m^2^) according to the CKD-EPI equation (eGFR~CKD-EPI~), age (years), sex and BMI (kg/m^2^). The following example illustrates how to interpret the table by using CKD-EPI in the CKD cohort: a female (bias 1.9 − 0.3) aged 45 (bias −2.8) with a BMI of 17 (bias 6.9) and an eGFR of 125 (bias 19.5) results in an estimated eGFR with a bias of 1.9 -- 0.3 -- 2.8 + 6.9 + 19.5 = 25.2 mL/min/1.73 m^2^.

The constant reflects the estimated bias for an individual that belong to the reference group in all four dimensions (eGFR, age, sex and BMI).

mGFR intervals \<30 were collapsed with 30 -- 59 due to small numbers.

DISCUSSION
==========

The salient finding of our comprehensive validation study is that prospects for improved GFR estimation based on creatinine still exist. The widely used CKD-EPI equation was generally sufficiently accurate with P~30~ exceeding 90% only in patients with low likelihood of CKD, but it was neither the most accurate equation in patients with known or suspected renal impairment nor the most accurate in young adults irrespective of their renal status. The FAS equation shared similar weaknesses as CKD-EPI when applied in the CKD cohorts and in young adults. LMR, on the other hand, was the most accurate equation among patients with high likelihood of CKD but did not perform as well in the community cohorts.

The explanation for the superior accuracy of LMR in patients with known or suspected renal impairment may be that the equation was formulated with the explicit goal to improve sensitivity (estimations in CKD patients) \[[@sfaa039-B21]\], whereas the goal of developing CKD-EPI was to improve specificity (estimations in patients with normal mGFR) \[[@sfaa039-B1]\]. The development of FAS was established from a mathematical construction based on age-average GFR and population-normalized serum creatinine valid for a healthy population \[[@sfaa039-B7], [@sfaa039-B22]\], which may explain its poor performance in patients with severe CKD.

The noticeable differences in performance depending on cohort type suggest that incorporation of prior information about the patient's disease history (e.g. pre-test probability of CKD) could improve estimation accuracy. More complex GFR estimation procedures, either rule-based choice of equation depending on clinical setting or machine learning algorithms \[[@sfaa039-B38]\], would open up the possibility of fine-grained estimations depending on, for example, age or pre-test probability of CKD. Such estimation procedures should ideally be applicable for the full age span of children, adults and older people, and use of cystatin C when available, and could also incorporate other patient characteristics such as height and weight to avoid overestimation of GFR in underweight patients. However, complex algorithms are often less transparent than explicitly formulated estimating equations, which means that a thorough assessment of algorithm fairness and accountability is warranted before implementation \[[@sfaa039-B39]\].

A major strength of the present study was the large sample size, which allowed for evaluation of diagnostic accuracy with sufficient statistical precision in three dimensions simultaneously (mGFR, age and sex). Another strength was the consistent stratification on cohort type in the evaluation of diagnostic predictiveness, as clinical presentation and related prevalence of CKD is fundamental for the interpretation of eGFR. This stratification, for example, highlighted how the expected error in eGFR as well as the influence of low BMI may differ importantly depending on clinical setting. Yet, another strength was that measurement of plasma/serum creatinine was based on enzymatic assays or directly measured with IDMS in all but two cohorts that only partly used Jaffe. A major limitation was that available data did not allow for separate validation in additional subgroups such as patients with diabetes, malignant disease or with organ transplantation, or other ethnicities than Europeans and non-black North Americans. The initial CKD-EPI study suggested that eGFR based on creatinine must be multiplied by a correction factor (1.159) to yield valid results for African Americans \[[@sfaa039-B1]\]. It seems logical to use the same correction factor for other creatinine-based equations such as LMR (or FAS) to extend their applicability to African Americans. However, we believe that differences in creatinine generation should be corrected at the creatinine level rather than at the GFR level to avoid misleading interpretations that GFR differs between ethnicities. This may be achieved using the approach implemented in the FAS equations \[[@sfaa039-B7], [@sfaa039-B40]\].

A potential limitation of the generalizability of the results is that the Swedish data constituted two-thirds of patients in the CKD cohorts. However, none of these cohorts has been used for the development of LMR. The results of the Swedish cohorts were consistent with those from another European centre, Lyon (France), insofar as LMR performed better than CKD-EPI, while the latter was more accurate in the North American Chronic Renal Insufficiency Cohort Study (CRIC) cohort ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S3](#sup1){ref-type="supplementary-material"}). One possible explanation for these divergent results may be differences in creatinine calibration. The CRIC study used Siemens creatinine enzymatic assay recalculated to the Roche Creatinine Plus assay, while the European cohorts all used enzymatic assays traceable to primary reference materials with values assigned by IDMS. Indirect creatinine calibration was also used in the development and initial validation of the CKD-EPI equation \[[@sfaa039-B1], [@sfaa039-B41]\], which may explain why this equation performs less well in CKD cohorts where creatinine assays directly traceable to IDMS are used \[[@sfaa039-B42]\]. Another explanation for diverging results across studies may be the use of different methods when measuring GFR. However, apart from renal clearance of inulin, considered the 'gold standard' for measuring GFR, renal clearance of iothalamate and ^51^Cr-EDTA as well as plasma clearance of iohexol have all been considered sufficiently accurate methods to measure GFR \[[@sfaa039-B32]\]. In addition, the single plasma sample method is highly concordant with a multiple sample strategy \[[@sfaa039-B43]\] providing that sampling time is adjusted according to estimated renal function \[[@sfaa039-B46]\] as used in the present cohorts.

In conclusion, the present study provides evidence that the widespread CKD-EPI equation is generally sufficiently accurate according to K/DOQI benchmark only in patients with low likelihood of CKD. Accuracy of GFR estimation based on creatinine can be improved in patients with known or suspected renal impairment and in young adults. Caution is necessary when using any of the three evaluated equations in clinical practice, as all exhibited considerable imprecision. Incorporation of the pre-test probability of CKD in the GFR estimation procedure can be an important step towards improved accuracy of eGFR across the full spectrum of age and renal function.
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